Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.25 EUR
Change Today 0.00 / 0.00%
Volume 14.1K
B8F On Other Exchanges
As of 2:20 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/14 - €3.28
52 Week Low
02/26/15 - €1.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; and Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

46 Employees
Last Reported Date: 04/10/15
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €405.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €202.0K
Compensation as of Fiscal Year 2014.

biofrontera ag (B8F) Key Developments

Biofrontera AG Delivers Excellent Results from the Phase Iii Study for Field Therapy of Actinic Keratosis for Publication

Biofrontera AG has prepared a scientific publication about the results of the multi-centre, placebo-controlled phase III study for field therapy of actinic keratosis using the combination of Biofrontera's prescription drug Ameluz® and PDT-lamp BF-RhodoLED®. Field therapy involves treating entire fields on the face or scalp covered with mild to moderate actinic keratosis with photodynamic treatment (PDT) with an entire tube of Ameluz® in combination with Biofrontera's PDT-lamp BF-RhodoLED®. Preliminary results of the phase III trial were first published in October 2014 and comprise a key component of the clinical program executed for the approval of Ameluz® in the US. With 90.9% of all patients fully cleared from all actinic keratoses, the combination of Ameluz® and BF-RhodoLED® provided excellent efficacy. After a maximum of two treatments clearance of the non-hyperkeratotic Olsen Grade I lesions1 reached 99.1%, that of the moderately hyperkeratotic Olsen Grade II lesions 91.7%. Completely eliminating all Olsen Grade I lesions is of particular importance since up to 63.8% of all squamous cell carcinomas originate from the less suspicious Olsen Grade I lesions. The cosmetic outcome of the treatment was assessed by the clinical investigators without taking the removal of the keratotic lesions into consideration. All tested parameters improved significantly during the treatment. The number of patients left without skin roughness, dryness, and scaliness increased from 14.8% to 63% after Ameluz® treatment. Patients without hyperpigmentation or hypopigmentation increased from 40.7% to 57.4% and 53.7% to 70.4%, respectively. Mottled pigmentation, including both hyper- and hypopigmentation within the treatment area, decreased from 48.1% of the patients to 29.6% of the patients, respectively. Before treatment, 22.2% of the patients displayed mild scarring, which after treatment was reduced to 14.8% of the patients. Atrophic skin tissue was apparent in 31.5% of the patients before, and in 16.7% of the patients after treatment.

Biofrontera AG Establishes Subsidiary in US; Appoints Monica Tamborini as CEO of US Operations

Biofrontera AG has formed a wholly-owned US subsidiary, Biofrontera Inc., registered in Wilmington, Delaware. This company is intended to lay the ground for marketing and sales activities upon the expected FDA approval for the products Ameluz and BF-RhodoLED in 2016. Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica has over 20 years experience managing US companies in the healthcare sector. Monica worked in various sectors before joining the pharmaceutical industry. Since then, Monica has held various positions as CFO and COO. In addition to her expertise in finance Monica has, as Managing Director of Calix Consulting.

Biofrontera AG Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2014; Provides Earnings Guidance for the Financial Year 2015

Biofrontera AG announced audited consolidated earnings results for the full year ended December 31, 2014. For the year, the company reported sales revenue of €3,095,555 against €3,114,551 a year ago. Loss from operations was €9,526,958 against €7,137,740 a year ago. Loss before income tax was €10,720,978 against €8,066,618 a year ago. Net loss for the year was €10,720,978 or €0.49 undiluted per share against €8,066,618 or €0.47 undiluted per share a year ago. Net cash flow into operations was €7,927,932 against €7,225,264 a year ago. Purchase of intangible and tangible assets was €164,082 against €341,980 a year ago. For the 2015 financial year, the company expects to achieve turnover of approximately €4 to €5 million, though this is still subject to significant planning uncertainties relating primarily to the speed of market penetration. The turnover forecast here does not include any additional licensing agreements with possible one-time payments. Moreover, the plans for 2015 do not take into consideration any down payment that may be made by a possible US sales partner, nor do they consider any additional costs that may be incurred if the company establishes its own sales division in the USA. The financial result reflects the interest payments and compounding of interest using the effective interest method for the two warrant bonds. Therefore, this will not significantly change in 2015 compared with 2014. The company will achieve a net loss of €9 to €10 million in 2015. The achievement of this result depends heavily on progress in terms of turnover.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.25 EUR 0.00

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies

Industry Analysis


Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at